Florida has reduced funding and tightened eligibility for its AIDS Drug Assistance Program, limiting access to the widely used HIV medication Biktarvy for thousands of patients, while more than 20 other states consider similar cuts amid rising program costs and stagnant federal funding.
Putting money directly in the hands of individuals to buy health insurance would unleash consumer forces, say supporters. Others see the plan as undercutting insurance markets and a “consumerism fantasy" with crucial details lacking.
Lindsay Greenleaf, J.D., MBA, and Nicolas Ferreyros offered insight and analysis during a March 3 webinar about healthcare policy and politics.
A recent American Cancer Society study found that colorectal cancer is increasingly common, especially in adults under 50. Test your current knowledge with this slideshow and learn what you can be doing to prevent it.
Juxtapid has been available to treat adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that causes extremely high levels of LDL cholesterol.
As World Obesity Day spotlights rising obesity rates, GLP-1s reshape treatment and coverage debates, with persistence, affordability and long-term value driving payer decisions.
A study published this week found that Black Medicare beneficiaries with early-stage NSCLC remain significantly less likely than White beneficiaries to receive curative treatment, largely because of lower surgery rates.
UT Southwestern researchers found that testosterone may increase susceptibility to staph infections by activating bacterial communication pathways.
The combination of acetaminophen and morphine provides slightly better early pain relief than morphine alone in emergency departments, particularly for patients with nontraumatic, nerve-related pain.
David Cordani is retiring after 17 years in the CEO role. he will join the board of directors as executive chair.
The first patient was enrolled in a trial of the inhaled insulin product for older children and adolescents who have been recently diagnosed with Type 1 diabetes.
Zahra Mahmoudjafari explains how cell and gene therapy programs succeed with strong infrastructure, pharmacy leadership, payer alignment, and workflows protecting safety and finances.
Tests for the DNA of the HPV virus might replace other ways of monitoring for recurrence in patients with cervical cancer.
The researchers caution, though, that causality cannot be inferred from the association found in an observational study.
A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma skin cancers.
Dhruv S. Kazi, M.D., a cardiologist at Beth Israel Deaconess Medical Center, discusses the research he and his team have done to determine if semaglutide used as secondary prevention of cardiovascular disease is cost-effective.
AI in managed care cuts documentation and burnout, but ROI, governance and transparency define success—learn what leaders must track and safeguard.
California health plans Blue Shield Promise and L.A. Care are partnering with the California Black Women’s Collective to help Black women in Los Angeles County gain career skills, mentorship and job opportunities through SheWorks California.
GLP‑1 drugs transform obesity and diabetes care, but soaring employer costs spark new coverage rules, safety concerns, and major pipeline updates.
Zahra Mahmoudjafari shares how The University of Kansas Cancer Center builds sustainable cell and gene therapy programs amid new CMS access rules.
A RAND analysis finds that provisions in the One Big Beautiful Bill Act will reduce Medicaid funding to states by hundreds of billions of dollars over the next decade, driven largely by new work requirements and more frequent eligibility redeterminations that are projected to lower enrollment by millions.
Researchers highlighted the anti-inflammatory benefits of GLP-1 receptor agonists in people with HIV, plus a growing concern over rising STI rates and the cautious promise of doxycycline post-exposure prophylaxis as a partial prevention strategy.
Sharon Faust, of Navitus Health Solutions, said in an interview that employers, health plans and manufacturers must work together to manage costs and access for patients taking GLP-1 medications.
In the first segment of a video interview with MHE, the CEO of Risant Health discusses the role of scale in following value-based practices.
ViiV Healthcare unveiled new data at the Conference on Retroviruses and Opportunistic Infections on next-generation long-acting HIV therapies.
Blocking the protein P2RX7 in regulatory T cells boosted antibody responses, and this discovery could one day lead to strategies for enhancing existing immunotherapies in non-small lung cancer.
Risant’s CEO, Jaewon Ryu, M.D., J.D., discusses some of the early successes of bringing a set of Kaiser Permanente’s value-based care practices to Risant's health systems—Geisinger Health in Pennsylvania and Cone Health in North Carolina. Consistency and "systemness” are key.
The president slammed the Affordable Care Act and talked up his Great Health Plan and his most favored nation drug pricing policies, highlighting lower prices for fertility drugs.
Cardinal Health 2026 Biosimilars Report shows biosimilars’ savings surge, but predictable reimbursement drives physician adoption amid FDA streamlining.
